In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia

β-地中海贫血的体内造血干细胞基因治疗

基本信息

批准号：
9000884
负责人：
ANDRE Michael LIEBER
金额：
$ 38.63万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-01 至 2020-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9000884
关键词：
AMD3100 Adenovirus Vector Adult Back Bone Marrow Bone Marrow Purging CD34 gene CD46 Antigen CSF3 gene Cells Collection Communicable Diseases DNA DNA cassette Erythroid Erythroid Cells Erythropoiesis Gene Delivery Gene Targeting Gene Transduction Agent Gene Transfer Genes Genetic Genomic Segment Globin Goals Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hemoglobin Hemolytic Anemia Hereditary Disease Home environment Human In Vitro Injection of therapeutic agent Lentivirus Vector Malignant Neoplasms Mediating Modeling Morbidity - disease rate Mus Mutation Patients Production Proteins Proto-Oncogenes Risk Safety Side Site Sleeping Beauty Stream System Systems Integration Testing Thalassemia Therapeutic Time Transfusion Transgenes Transgenic Mice Transgenic Model Transplantation Transposase Ursidae Family base beta Thalassemia cellular transduction cost epigenetic regulation gene therapy genome editing genotoxicity gutless adenoviral vector homologous recombination in vivo intravenous injection mouse model peripheral blood public health relevance receptor retransplantation transcription activator-like effector nucleases transgene expression vector

项目摘要

DESCRIPTION (provided by applicant) Hematopoietic stem cells (HSCs) are an important target for the gene therapy of infectious diseases, genetic disorders, and cancer. In vivo genome editing of HSCs has major advantages over currently used approaches that involve the collection of HSCs from patients, their in vitro culture/transduction, and retransplantation into myelo-conditioned patients. We have developed a new in vivo approach for HSC transduction, which is based on the GCSF/AMD3100-mediated mobilization of HSCs from the bone marrow into the peripheral blood stream and the intravenous injection of an HSC-targeting, helper-dependent adenovirus vector (HD-Ad5/35). The central goal of this proposal is to increase the percentage of stably in vivo HD-Ad5/35 - transduced HSCs while avoiding potential genotoxicity. We plan to achieve this through i) optimization of HSC mobilization and in vivo HSC transduction, ii) optimization of transgene integration through stimulation of homologous recombination, and iii) incorporation into HD- Ad5/35 vectors of systems that allow for the in vivo selection or expansion of stably transduced cells. Based on these studies, we will generate and test HD-Ad5/35 vectors for in vivo gene therapy of b-thalassemia.

描述（由申请人提供）造血干细胞（HSC）是传染病，遗传疾病和癌症基因治疗的重要靶标。 HSC的体内基因组编辑比当前使用的方法具有很大的优势，该方法涉及从患者那里收集HSC，其体外培养/转导以及重新植入到髓条调节患者中。我们已经开发了一种用于HSC转导的新型体内方法，该方法基于GCSF/AMD3100介导的HSC从骨髓中移动到外周血流，并静脉注射HSC靶向HSC靶向HSC靶标，依赖HSC的腺病毒载体载体（HD-AD-AD5/35）。该提案的核心目标是增加体内HD -AD5/35-转移的HSC的稳定百分比，同时避免潜在的遗传毒性。我们计划通过i）i）优化HSC动员和体内HSC转导，ii）通过刺激同源重组的刺激优化转化整合，以及III）掺入了HD-AD5/35载体中，以允许体内选择或稳定翻译细胞的体内选择或扩展。基于这些研究，我们将生成和测试HD-AD5/35载体，以用于体内基因疗法B- thalass省。